Our Grants

CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.

See our complete portfolio of awards below.

View Funded Institutions
View Funded Investigators
Find Clinical Trials

All CIRM Grants

Search Filters »

Institution Researcher name Grant Type Grant Title Award Value
City of Hope, Beckman Research Institute Prof. John A. Zaia Disease Team Research I ZINC FINGER NUCLEASE-BASED STEM CELL THERAPY FOR AIDS $14,536,969
University of Southern California Mark Salman Humayun Disease Team Research I Stem cell based treatment strategy for Age-related Macular Degeneration (AMD) $18,904,916
University of California, San Diego Dr. Dennis A Carson Disease Team Research I Development of Highly Active Anti-Leukemia Stem Cell Therapy (HALT) $19,999,826
University of California, San Diego Dr. Gene Wei-Ming Yeo Basic Biology I RNA Binding Protein-mediated Post-transcriptional Networks Regulating HPSC Pluripotency $1,308,901
University of California, San Diego Karl H. Willert Basic Biology I WNT signaling and the control of cell fate decisions in human pluripotent stem cells. $1,329,298
University of California, Davis Dr. Min Zhao Basic Biology I Directing migration of human stem cells with electric fields $816,228
University of California, Los Angeles Dr. Michael A. Teitell Basic Biology I Mitochondrial Metabolism in hESC and hiPSC Differentiation, Reprogramming, and Cancer $1,323,029
University of Southern California Dr. Martin Pera Basic Biology I The stem cell microenvironment in the maintenance of pluripotency and reprogramming $1,325,723
Stanford University Dr. Julien Sage Basic Biology I The retinoblastoma (RB) gene family in cellular reprogramming $1,357,085
Stanford University Dr. Susan K McConnell Basic Biology I Identification and characterization of human ES-derived DA neuronal subtypes $1,404,853
University of California, Los Angeles Bennett G Novitch Basic Biology I Molecular Characterization of hESC and hIPSC-Derived Spinal Motor Neurons $1,228,278
University of California, Los Angeles Dr. Robb Maclellan Dr. Basic Biology I Human Cardiovascular Progenitors, their Niches and Control of Self-renewal and Cell Fate $917,667
University of Southern California Dr. Wange Lu Basic Biology I Defining the molecular mechanisms of somatic cell reprogramming $1,365,580
Stanford University Professor Helen M. Blau PhD Basic Biology I Molecular Mechanisms of Reprogramming towards Pluripotency $1,408,332
University of California, Los Angeles Dr. Luisa Iruela-Arispe Basic Biology I Molecular Characterization and Functional Exploration of Hemogenic Endothelium $1,371,477
University of California, San Diego Christian Metallo Basic Biology V Metabolic regulation of cardiac differentiation and maturation $1,124,834
University of California, Los Angeles Dr Samantha J Butler Ph.D. Basic Biology V Assessing the mechanism by which the Bone Morphogenetic Proteins direct stem cell fate $515,730
Cedars-Sinai Medical Center Paul W Noble Basic Biology V Innate Immune Regulation of Lung Alveolar Stem Cell Renewal in Mouse and Man $617,662
Gladstone Institutes, J. David Sheng Ding PhD Basic Biology V A novel druggable mechanism to safeguard stem cell genome $1,294,495
University of California, San Francisco Dr. Mark S. Anderson Basic Biology V Generation of a functional thymus to induce immune tolerance to stem cell derivatives $1,191,000
University of California, Irvine Dr. Lisa A Flanagan Basic Biology V Molecular basis of plasma membrane characteristics reflecting stem cell fate potential $994,108
University of California, San Diego Maike Sander Basic Biology V Defining links between chromatin state and developmental competence $1,050,300
University of Southern California Dr. Denis A Evseenko Dr. Basic Biology V Promoting survival and countering hypertrophy of pluripotent stem cell (PSC)-derived chondrocytes $735,138
University of California, Los Angeles Dr. Denis A Evseenko Dr. Basic Biology V Promoting survival and countering hypertrophy of pluripotent stem cell (PSC)-derived chondrocytes $411,330
University of California, San Diego Miles F Wilkinson Basic Biology V New Regulators of Spermatogonial Stem Cells: RHOX Homeobox Transcription Factors $552,811
University of California, Los Angeles Dr. Lili Yang Basic Biology V Differentiation of Human Hematopoietic Stem Cells into iNKT Cells $614,400
University of California, San Diego Dr. Cornelis Murre Basic Biology V Epigenetic mechanisms that enforce pluripotency in embryonic stem cells $1,160,997
University of California, San Diego Dr. Wei Wang Basic Biology V Systems-level discovery of the regulatory mechanisms directing differentiation of hESC $1,161,000
University of California, San Diego Dr. Lawrence S. B. Goldstein Basic Biology V Elucidating pathways from hereditary Alzheimer mutations to pathological tau phenotypes $1,050,300
University of California, San Diego Dr. David A. Cheresh Basic Biology V CD61-driven stemness program in epithelial cancer $1,161,000
University of California, Berkeley Dr. Andrew Dillin Basic Biology V A Requirement for Protein Homeostasis in the Mediation of Stem Cell Health $1,034,100
Stanford University Xinnan Wang Basic Biology V Misregulated Mitophagy in Parkinsonian Neurodegeneration $1,174,943
University of Southern California Mark Salman Humayun Disease Team Therapy Development III Phase 1 Safety Assessment of CPCB-RPE1, hESC-derived RPE Cell Coated Parylene Membrane Implants, in Patients with Advanced Dry Age Related Macular Degeneration $16,339,827
University of California, Davis Peter Belafsky Disease Team Therapy Development III Tissue Engineered Recellularized Laryngotracheal Implants $3,181,162
University of California, Los Angeles Dr. Dennis J Slamon Disease Team Therapy Development III A Phase I dose escalation and expansion clinical trial of the novel first-in-class Polo-like Kinase 4 (PLK4) inhibitor, CFI-400945 in patients with advanced solid tumors $5,683,693
Stanford University Professor Irving L Weissman MD Disease Team Therapy Development III Clinical Investigation of a Humanized Anti-CD47 Antibody in Targeting Cancer Stem Cells in Hematologic Malignancies and Solid Tumors $6,505,568
University of California, Los Angeles Dr. Donald B. Kohn Disease Team Therapy Development III Clinical Trial of Stem Cell Gene Therapy for Sickle Cell Disease $10,351,535
University of California, San Diego Thomas J Kipps Disease Team Therapy Development III Therapeutic Eradication of Cancer Stem Cells with UC-961 (Cirmtuzumab) $4,179,598
Sangamo BioSciences, Inc. Dr. Fyodor D Urnov Strategic Partnership II A Treatment For Beta-thalassemia via High-Efficiency Targeted Genome Editing of Hematopoietic Stem Cells $2,760,540
Human BioMolecular Research Institute Dr. John R Cashman Ph.D. Patent Assistance Fund Awards Intellectual Property for Stem Cell-Related Inventions – HBRI $50,000
University of California, San Francisco Karin Immergluck PhD Patent Assistance Fund Awards Patent Assistance Fund Proposal – UCSF $87,257
University of California, Davis David McGee Patent Assistance Fund Awards CIRM Patent Prosecution Assistance Fund for Stem Cell Technologies – UCD $48,595
University of California, Santa Barbara Bernadette McCafferty Patent Assistance Fund Awards Intellectual Property in Regenerative Bioengineering from CIRM funded research in regenerative medicine at the University of California, Santa Barbara. $23,564
University of California, Irvine Ronnie Hanecak Patent Assistance Fund Awards CIRM Patent Assistance Fund Application – UCI $46,155
University of California, Los Angeles Adele Rennie Patent Assistance Fund Awards Patent Assistance Fund – UCLA $84,973
Stanford University Katharine Ku Patent Assistance Fund Awards Funding for Patent Applications for CIRM-funded Inventions out of Stanford University $3,525
University of California, San Diego Dr. Rubén D. Flores Patent Assistance Fund Awards Patent Assistance Fund Application – UCSD $38,162
University of California, San Diego Dr. Lawrence S. B. Goldstein Early Translational from Disease Team Conversion Stem Cell-Derived Astrocyte Precursor Transplants in Amyotrophic Lateral Sclerosis $4,139,754
University of California, Los Angeles Dr. Irvin SY Chen Early Translational from Disease Team Conversion Development of a humanized mouse model for testing anti-HIV HSPC gene therapy strategies in HIV-1 infected mice. $1,505,000
University of California, Los Angeles Dr. Stanley Nelson Early Translational from Disease Team Conversion Combination therapy to Enhance Antisense Mediated Exon Skipping for Duchenne Muscular Dystrophy $1,823,545
1 2 3 4 5 6 7 8 9 10 11 … 33